tirzepatide and psoriatic arthritis A Study to Investigate Effectiveness of Following Initiation of Ixekizumab in Participants With Active Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) Concomitant tirzepatide and ixekizumab significantly

Brief exposure (under 30 minutes) during dose preparation is fine

Brazilian Journal of Pharmaceutical Sciences, 55

Steinberg, H

The follow-up time for each individual was divided into three time periods: (1) pretreatment (12 months before initiation), (2) initial exposed period (0-12 months), and (3) late exposed period (13-24 months)

Some research protocols account for this by using comparatively lower dosing ranges in female study cohorts, reflecting a generally increased sensitivity to IGF-1 receptor activation a pattern also documented in broader growth hormone axis research, not unique to IGF-1 LR3 specifically